Tumor Infiltrating Lymphocytes Adjuvant Therapy of Melanoma

Summary

The objective of this multicentric Phase III study is to confirm the results of the phase I-II study (Dreno B \& Al. Cancer Immunol Immunother 2002; 51: 539-456) which demonstrated the preventive effect of a treatment by TIL (Tumor Infiltrating Lymphocytes) combined with IL2 (Interleukin 2; low dose injected subcutaneously) on the metastatic relapse in the stage III melanoma patients with only one invaded lymphnode.

Timeline

Start

2005-05

Primary completion

2012-03

Completion

2012-03

Drugs

Indications